ClinicalTrials.gg
Enrolling by invitationNCT05880069Updated May 30, 2023

Clinical Outcomes in Patients With Infection by Resistant Microorganism

An observational study in Pneumonia, Bloodstream Infection and Urinary Tract Infections, sponsored by Hospital Universitario Virgen Macarena. Enrolling by invitation at 1 site in Spain. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Hospital Universitario Virgen Macarena · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 5 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Pneumonia with a site in Spain — 12 open to participants now, 13 under way, 4 of them phase 3. Pneumonia · Spain.

Planned enrollment
4th of 12
5,000 · median 763
Started
2022
with 4 others
Observational
12 of 79
2 open now
Primary completion
2023-06
later than 0 of 12 live
Registered
68th of 79
by date

Among the 79 studies in Pneumonia with a site in Spain, this one is the 4th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2022, is one of 12 observational ones, reaches primary completion later than 0 of the 12 other live ones, and was the 68th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

12 of the 79 studies in Pneumonia with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Pneumonia with a site in Spain, or all of them as a file.
02

Study summary

The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and urinary tract infections, caused by target drug-resistant pathogens, in high income countries.

The main question[s] it aims to answer are:

  • Are common infections caused by drug-resistant pathogens associated with an increased health burden, when compared with individuals with the same infection caused by a susceptible strain (attributed burden)?
  • Are common infections caused by drug-resistant pathogens associated with an increase health burden, when compared with individuals without the infection under study (associated burden)?
03

Conditions studied

  • Pneumonia
  • Bloodstream Infection
  • Urinary Tract Infections
  • Skin Infection
  • Surgical Site Infection
  • Staphylococcus Aureus
  • Klebsiella Pneumonia
  • Escherichia Coli
  • Enterococcus Faecium Infection
  • Acinetobacter Infections
  • Pseudomonas Aeruginosa
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

  1. Individuals of all ages with the target pathogen, resistance phenotype, and infection site combinations as follows:

    • P. aeruginosa, carbapenems resistant: BSI
    • A. baumannii, carbapenems resistant: BSI
    • E. coli, 3rd generation cephalosporins resistant: BSI and UTI
    • K. pneumoniae, 3rd generation cephalosporins resistant: BSI
    • K. pneumoniae, carbapenems resistant: BSI
    • S. aureus, methicillin resistant: BSI, pneumonia, SSI and SSTI
    • E faecium, vancomycin resistant: BSI
    • Enterobacterales, 3rd generation cephalosporins resistant: BSI
  2. Individuals of all ages with the same infection caused by the target drug-susceptible pathogen
  3. Individuals of all ages without the infection under study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals of all ages
  • Individuals with hospital acquired, community acquired, or healthcare associated infections
  • Individuals treated at hospital level, community, or long-term care facilities
  • Individuals with the targeted pathogen, resistance phenotype, and infection site combinations under study

Exclusion criteria

Exclusion Criteria:

  • Individuals with infections in the following systems: central nervous system, genital system, pelvic infections and head and neck infections
  • Individuals with the following specific primary infections: endocarditis, upper respiratory tract infections, lung abscess
  • Individuals with bacterial infections not included in the table of pathogens of interest, polymicrobial infections except for intraabdominal infections, fungal infections, parasitic infections, viral infections, mycobacterial infections, sexually transmitted diseases, and zoonotic infections
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Drug-resistant pathogen

    Individuals of all ages with the target pathogen, resistance phenotype, and infection site combinations as follows: 1. P. aeruginosa, carbapenems resistant: BSI 2. A. baumannii, carbapenems resistant: BSI 3. E. coli, 3rd generation cephalosporins resistant: BSI and UTI 4. K. pneumoniae, 3rd generation cephalosporins resistant: BSI 5. K. pneumoniae, carbapenems resistant: BSI 6. S. aureus, methicillin resistant: BSI, pneumonia, SSI and SSTI 7. E faecium, vancomycin resistant: BSI 8. Enterobacterales, 3rd generation cephalosporins resistant: BSI

    Other: Pathogen resistant phenotype

  • Drug-susceptible pathogen

    Individuals of all ages with the target pathogen, susceptible phenotype, and infection site combinations as follows: 1. P. aeruginosa, carbapenems susceptible: BSI 2. A. baumannii, carbapenems susceptible: BSI 3. E. coli, 3rd generation cephalosporins susceptible: BSI and UTI 4. K. pneumoniae, 3rd generation cephalosporins susceptible: BSI 5. K. pneumoniae, carbapenems susceptible: BSI 6. S. aureus, methicillin susceptible: BSI, pneumonia, SSI and SSTI 7. E faecium, vancomycin susceptible: BSI 8. Enterobacterales, 3rd generation cephalosporins susceptible: BSI

    Other: Pathogen resistant phenotype

  • No infection

    Individuals of all ages without the infection under study

Interventions

  • OtherPathogen resistant phenotype

    Drug resistant phenotype of the target pathogen under study

06

What researchers measure

Primary outcomes

  1. Mortality

    Death any time after infection, during the follow-up time of the original study.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Number of participants with ICU admission

    Need for an admission in ICU setting for more than 24 hours after infection onset.

    Time frame: Through study completion, an average of 1 year

  2. Number of participants with clinical cure

    Absence of symptoms after completion of an antibiotic treatment course.

    Time frame: Through study completion, an average of 1 year

  3. Number of participants with microbiological cure

    No isolation of the causal microorganisms after completion of an antibiotic treatment course.

    Time frame: Through study completion, an average of 1 year

  4. Number of participants with recurrence of infection

    Infection with the same organism after more than two weeks of the initial infection.

    Time frame: Through study completion, an average of 1 year

  5. Number of participants with superinfection

    Other infections different from the one under assessment.

    Time frame: Through study completion, an average of 1 year

  6. Number of participants with cognitive impairment / disability

    Impairment is any temporal or permanent loss of function; disability is a restriction or inability to perform a normal activity resulting from an impairment. Assessed using Center for Epidemiologic Studies Depression Scale (CES-D), Mini-Mental State Examination (MMSE) or Trail Making Test (TMT).

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jun 2023, 8 months after the start.

Of 210 non-industry observational studies under Pneumonia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 8 months is below that.

Counting every sponsor, half of 223 studies reached it within 27 months; a quarter within 13 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
May 30, 2023
StartActual
Oct 1, 2022
Primary completionEst.
Jun 2023
CompletionEst.
Oct 2023
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05880069
Lead sponsor
Hospital Universitario Virgen Macarena
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Oct 1, 2022
Primary completion
Jun 2023 (estimated)
Completion
Oct 2023 (estimated)
Last update
May 30, 2023

Study contacts

Jesús Rodríguez-Baño, MD PhD
study director · Unidad Clínica de Enfermedades Infecciosas, Microbiología. Hospital Universitario Virgen Macarena

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion